Xbrane And Biogen Ally On Certolizumab Pegol Biosimilar

Xbrane CEO Martin Åmark Highlights Potential For Xcimzane Rival To Cimzia

Xbrane Biopharma and Biogen have struck a licensing deal for Xbrane’s Xcimzane certolizumab pegol proposed biosimilar rival to Cimzia. In the wake of the announcement, Xbrane CEO Martin Åmark offered details on the partnership as well as the product’s commercial potential.

Certolizumab Pegol green background
Xbrane has secured Biogen as a partner on its Xcimzane certolizumab pegol biosimilar • Source: molekuul.be / Alamy Stock Photo

Xbrane Biopharma and Biogen have struck a global licensing and commercialization deal for Xbrane’s Xcimzane (certolizumab pegol) proposed biosimilar rival to Cimzia that is currently at the pre-clinical stage. Through the agreement, Biogen will gain exclusive global regulatory, manufacturing and commercial rights to Xcimzane and will be the marketing authorization holder for the biosimilar.

More from Deals

More from Business